mGluR8 Inhibitors for mGluR8-Associated Cancer Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cancer treatments are inadequate in addressing the rising incidence and mortality rates of cancer, particularly due to the limited effectiveness of existing therapies for mGluR8-associated cancers.
Innovation Solution
The use of metabotropic glutamate receptor 8 (mGluR8) inhibitors, such as mGluR8 inhibitory antibodies and small molecules, to treat cancer by administering them to subjects, contacting immune cells or tumors, and modulating immune cell activity to increase pro-inflammatory cytokine production and immune cell function.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional cancer treatments are used, then treatment coverage is provided for general cancer cases, but effectiveness is insufficient for mGluR8-associated cancers
Solution Approach 1:
The patent applies local quality by developing an immunotherapy composition specifically tailored for mGluR8-associated cancers. The composition includes mGluR8 inhibitory antibodies that selectively target the mGluR8 receptor pathway, providing localized therapeutic action against cancers with specific mGluR8 expression patterns while leaving other cancer types unaffected. This specificity is achieved through the selective binding of the antibody to mGluR8 receptors on tumor cells or associated immune cells.
Solution Approach 2:
The patent employs parameter changes by modifying the immune system's response parameters through the administration of mGluR8 inhibitory antibodies. The composition alters key immunological parameters including cytokine production levels (particularly IL-8), immune cell activation states, and inflammatory responses. These parameter changes enable the immune system to effectively recognize and attack mGluR8-associated cancers that were previously resistant to conventional therapies.
2Reliability
If mGluR8 inhibitors are administered to treat cancer, then treatment effectiveness for mGluR8-associated cancers is improved, but treatment specificity must be maintained to avoid off-target effects
Solution Approach 1:
The patent uses an intermediary approach by employing mGluR8 inhibitory antibodies as mediators between the immune system and cancer cells. These antibodies specifically bind to mGluR8 receptors, acting as intermediaries that trigger immune responses against target cells expressing mGluR8 while leaving cells without this receptor unaffected. This intermediary mechanism ensures high treatment efficacy for mGluR8-associated cancers while minimizing off-target effects on healthy tissues.
3Productivity
If immune cell activity is enhanced to treat cancer, then anti-tumor immunity is increased, but immune system modulation complexity increases
Solution Approach 1:
The patent applies the taking out principle by extracting and isolating the specific mGluR8 inhibitory antibody component from complex immunotherapy approaches. Rather than using combination therapies or genetically modified cells, the invention focuses on a single well-defined molecular entity (the mGluR8 inhibitory antibody) that can be administered systemically. This extraction of the key active component simplifies the overall treatment mechanism while maintaining high immune cell activation and anti-tumor efficacy.
Data Source
AI summary
The present invention provides methods for treating cancer using mGluR8 inhibitors, such as mGluR8 inhibitory antibodies and small molecules. The invention also features compositions containing mGluR8 inhibitors, methods of diagnosing patients with mGluR8-associated cancer, and methods of predicting the response of cancer in a subject to treatment with mGluR8 inhibitors.